Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Diagnosis, treatment and prevention of pediatric obesity: consensus position statement of the Italian Society for Pediatric Endocrinology and Diabetology and the Italian Society of Pediatrics

Abstract

The Italian Consensus Position Statement on Diagnosis, Treatment and Prevention of Obesity in Children and Adolescents integrates and updates the previous guidelines to deliver an evidence based approach to the disease. The following areas were reviewed: (1) obesity definition and causes of secondary obesity; (2) physical and psychosocial comorbidities; (3) treatment and care settings; (4) prevention.

The main novelties deriving from the Italian experience lie in the definition, screening of the cardiometabolic and hepatic risk factors and the endorsement of a staged approach to treatment. The evidence based efficacy of behavioral intervention versus pharmacological or surgical treatments is reported. Lastly, the prevention by promoting healthful diet, physical activity, sleep pattern, and environment is strongly recommended since the intrauterine phase.

Background

Contrasting pediatric obesity is among the priority goals in the healthcare agenda of the Italian National Healthcare System. Beyond the high prevalence and persistence of pediatric obesity [1], robust evidence demonstrates that physical and psychosocial complications are already present in obese children [2] and worsen in adulthood. Therefore, prevention and treatment of pediatric obesity and complications are key strategic goals, in order to reduce morbidity, mortality, and expected costs for the care of obese adults.

The very fruitful scientific research on pediatric obesity of the last decade justified to update the guidelines, in order to provide the best evidence-based reccomendations. Therefore, the Italian Society for Pediatric Endocrinology and Diabetology and the Italian Society of Pediatrics, with other Pediatric Societies joined in the common objective of contrasting pediatric obesity, made this Consensus on “Diagnosis, therapy and prevention of obesity in children and adolescents”, updating the document published in 2006 [3].

Methods

Four main topics were defined: 1) diagnostic criteria, secondary obesity; 2) comorbidities; 3) treatment and care settings; 4) prevention. Coordinators were identified for each topic and specific questions listed. Twenty experts’ groups were set up, embracing all the skills needed for document processing. Each group systematically revised the literature on the assigned themes limited to the time frame 1 January 2006 to 31 May 2016 and patients’ age range 0–18 years. The article search was done through PubMed using MeSH terms or descriptors. Scientific articles, systematic reviews, meta-analysis, consensus, recommendations, international and national guidelines published on pediatric obesity even prior to 2005 were considered and deemed useful to the Consensus. The level of evidence (LOE) and the grade of raccomendation were established in accordance with the National Manual of Guidelines [4] (Additional file 1). Each working group prepared a preliminary draft reporting LOE for each specific recommendation, followed by a brief description of the scientific evidence in support, epidemiological data, and any notes deemed as useful. A Consensus Conference was held in Verona, on June 9th, 2016 in the presence of the document extensors and delegates of the Scientific Societies to discuss and approve the preliminary draft. The final document was sent on October 10th, 2016 to all the extensors and members of the Pediatric Obesity Study Group of the Italian Society for Pediatric Endocrinology and Diabetology and approved on 28th February 2017 in its definitive form. Literature search was updated before preparing the final draft; no additional relevant publication was identified which might have required a change in the statements.

Diagnosis

Diagnostic criteria for defining overweight, obesity and severe obesity

The definition of overweight and obesity is based on the use of percentiles of the weight-to-length ratio or body mass index, depending on sex and age. LOE V-A

In children up to 24 months, the diagnosis of overweight and obesity is based on the weight-to-length ratio, using the World Health Organization (WHO) 2006 reference curves [5]. After the age of 2 years it is based on the Body Mass Index (BMI), using the WHO 2006 reference system [5] up to 5 years and the WHO 2007 reference system [6] thereafter (Table 1). The recommendation of using the WHO standard is based on the need to propose a reference system which, although is not an ideal model to assess adiposity in single children or groups, it has a greater sensitivity in identifying children and adolescents with overweight and obesity, in a period of particular seriousness of the pediatric obesity epidemic in Italy. On the contrary, the Italian BMI thresholds [7] underestimate the prevalence of obesity compared to WHO, probably because they were based on measurements taken during the epidemic increase of obesity [8].

Table 1 Diagnostic criteria to classify overweight and obesity

The cut-off to define severe obesity is represented by the BMI > 99th percentile. LOE VI-B

It has been demonstrated that the 99th percentile of BMI identifies subjects with higher prevalence of cardiometabolic risk factors and persistence of severe obesity in adulthood with respect to the lower percentiles [9]. The WHO system provides the values of the 99th percentile of BMI which approximate + 3 SDS from 2 years upwards. However, as for overweight and obesity classification, the WHO terminology for severe obesity differs between younger (0–5 years) and older children/adolescents (5–18 years): the 99th percentile identifies “obesity” in the former group, and “severe obesity”in the latter. This cautious approach is motivated by the fact that the growth process differs between younger and older children; moreover few data are available on the functional significance of the cut-offs for the upper end of the BMI-for-age distribution in pre-school age [10, 11]. A scientific statement from the American Hearth Association proposed the 120% above the age and sex 95th percentile of BMI or an absolute BMI ≥ 35 kg/m2 (equivalent to class 2 obesity in adults) as an alternative to the 99th percentile [12]. The impact of this system using the WHO thresholds has yet to be assessed in clinical practice.

Secondary obesity

The clinical suspicion of secondary obesity arises after careful anamnestic, anthropometric and clinical evaluations. LOE III-A

Obesity may be ascribed to a specific cause (endocrine, hypothalamic, genetic, iatrogenic). Therefore, clinical history, peculiar signs and symptoms must be accurately assessed such as: 1) onset of obesity before 5 years and/or rapid progression, especially in association with clues suggesting secondary causes (i.e. genetic forms); 2) continuous and/or rapid weight gain associated with reduced height velocity or short stature; 3) delayed cognitive development; 4) dismorphic features; and 5) use of drugs inducing hyperphagia (i.e. corticosteroids, sodium valproate, risperidone, phenothiazines, ciproeptadine) [13].

Early-onset obesity occurring in a child with delayed psychomotor development, cognitive deficiency, short stature, cryptorchidism or hypogonadism, dysmorphisms and characteristic facial features, ocular and/or auditory alterations, is suggestive of a syndromic form [14]. Prader-Willi syndrome is the most common one, whereas Bardet-Biedl, Alström, Cohen, Borjeson-Forssman and Carpenter are more rarely observed [15,16,17,18,19,20]. Obesity occurs frequently in children with trisomy 21, Klinefelter and Turner syndromes [21,22,23].

The monogenic forms, albeit uncommon, are nevertheless the most frequent causes of obesity with early onset compared to endocrine and syndromic forms [24] and are due to dysregulated hunger satiety circuits [25]. Certain monogenic forms are characterized by tall or normal stature [14]. Suspicion of syndromic or monogenic forms is confirmed by genetic investigations.

Comorbidities

Hypertension

Blood pressure measurement is recommended in all children with overweight or obesity from the age of 3 years. LOE I-A

Obesity is the main risk factor for hypertension in children and adolescents [26, 27]. The risk increases with obesity severity [28]. As blood pressure (BP) levels change according to sex, age, ethnicity and obesity, the prevalence of high BP levels and especially hypertension is heterogeneous (7–30%) in obese children [29, 30]. White coat hypertension may cause overestimation of the high BP prevalence, but the effect tends to disappear if BP is measured on at least 2–3 occasions [29].

Screening can be anticipated in children < 3 years if there is a history of neonatal complications, cardiac malformations, genetic diseases, acquired or congenital kidney diseases, neoplasms, drug use, illnesses which induce increased intra-cranial pressure [31] (LOE III-B).

The definition of high BP levels requires a precise methodology and the use of tables expressing by sex and age the percentile of systolic and diastolic blood pressure as a function of the height percentile. LOE III-A

The method of measuring BP and the definition of high systolic (SBP) and diastolic BP (DBP) values are based on the guidelines of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents and the European Society for Hypertension (Table 2) [32, 33].

Table 2 Definition of the blood pressure values

Primary forms of hypertension are mainly associated with obesity and more frequent in children > 6 years. Secondary forms are predominant in younger children. Nephropathy, nephrovascular pathologies and coarctation of the aorta account for 70–90% of the causes of secondary hypertension in pediatric age, while hypertension by endocrine causes is rare [34]. Various drugs (steroids, erythropoietin, theophylline, beta-stimulants, cyclosporin, tacrolimus, tricyclic antidepressants, antipsychotics, monoamino oxidase inhibitors, nasal decongestants, oral contraceptives, and androgens) can increase BP. If stage I hypertension is confirmed on 3 different visits, the following diagnostic work-up is recommended: 1) assessment of blood urea nitrogen, creatinine, glycemia, electrolytes, lipids, urine examination, microalbuminuria (may be influenced by physical activity) (LOE II-A); 2) measurement of glomerular filtration by formulas for renal function monitorig (LOE III-B); 3) echocardiography to assess organ damage (left ventricular hypertrophy, altered cardiac structure) (LOE III-A) [35]. Left ventricular remodeling or concentric hypertrophy are associated with high BP levels and other comorbidities such as visceral obesity and atherogenic dyslipidemia [36, 37]. Weight loss and reduced sodium intake are recommended. If stage II hypertension or secondary causes are present, the patient must be referred to a specialist for further investigations and treatment [31, 34, 35].

Prediabetes and type 2 diabetes mellitus

Fasting blood glucose measurement is recommended in all children and adolescents with overweight and obesity since the age of 6, as the first step for screening prediabetes and type 2 diabetes. LOE V-A

The diagnosis of prediabetes, i.e. high fasting blood glucose and impaired glucose tolerance (IGT) or overt type 2 diabetes (T2D) is based on fasting plasma glucose or oral glucose tolerance test (OGTT) [38]. The use of hemoglobin glycosilated A1c (HbA1c) is still controversial in pediatric age [38,39,40,41,42]. The criteria for defining prediabetes and T2D are summarized in Table 3. The screening must be repeated after 3 years, unless rapid weight increase or the development of other cardiometabolic comorbidities occur. Since evidences provided from national studies suggest that prediabetes is already present in about 5% obese children < 10 years [43], it is recommended to start the screening by testing fasting glucose in all overweight or obese children after the age of 6 years. The OGTT is indicated after the age of 10 years or at onset of puberty in agreement with the criteria of the American Diabetes Association [38] (Table 4). Certain conditions, such as non-alcoholic fatty liver disease (NAFLD), fasting blood glucose ≥86 mg/dl, or a combination of triglycerides (TG) > 100 mg/dl plus fasting blood glucose > 80 mg/dl, or TG to HDL-cholesterol ratio (TG/HDL-C) ≥2.2, have been associated with increased risk of IGT [44,45,46,47] and therefore, an OGTT may be considered in latter cases (LOE VI-B) (Table 4).

Table 3 Criteria for the diagnosis of prediabetes and diabetes mellitus
Table 4 Indication for the oral glucose tolerance test in children and adolescents with overweight or obesity

Dyslipidemia

The measurement of cholesterol, HDL-cholesterol and triglycerides is recommended in all children and adolescents with obesity since the age of 6. LOE I-A

The dyslipidemic pattern associated with childhood obesity consists of a combination of elevated TG, decreased HDL-C, and low density lipoprotein cholesterol. The prevalence of dyslipidemia among obese children was 46–50.4% [48, 49]. Because the association of obesity/hyperlipidemia (expecially hypertriglyceridemia) is predictive of fatal and non fatal cardiovascular events in adult life [50], the screening of dyslipidemia is recommended, and should be repeated after 3 years, if negative, or more frequently if rapid increase in weight or development of other cardiometabolic comorbidities occurs [51, 52].

In the absence of national reference values, the diagnosis of dyslipidemia is based on the criteria proposed by the expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents. LOE III-B

The cut-offs for the definition of abnormal lipid levels as proposed by the Expert Panel [51] are summarized in Table 5. Recent studies have shown that the TG/HDL-C ratio is associated with insulin resistance and early organ damage (heart, liver, and carotid) [53,54,55]. The Tg/HDL-C > 2.2 can be considered as a marker of atherogenic dyslipidemia and an altered cardiometabolic risk profile in obese children in Italy [55, 56] (LOE V-A). Children with TG ≥ 500 mg/dL or LDL-Cholesterol persistently ≥ 160 mg/dL need lipid specialist consultation [51].

Table 5 References values to define dyslipidemia according to the Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents60

Gastroenterological complications

Non-alcoholic fatty liver disease

The assessment of transaminases and liver ultrasound is suggested in all children and adolescents with obesity starting at age of 6 years. LOE V-B

The prevalence of NAFLD in obese children is 38–46% [57, 58]. Bright liver on ultrasound examination, with or without elevation of alanine aminotransferase (> 26 U/L in boys and > 22 U/L in girls) suggests NAFLD [59]. Weight reduction and re-testing after 6 months are initially recommended [60] (LOE III-A). If liver hyperechogenicity and/or elevated alanine aminotransferase persist despite weight loss, other causes of hepatic disease (i.e. viral hepatitis, Wilson’s disease, autoimmune hepatitis, alpha 1 anti-tripsin deficiency, etc.) should be investigated. If ALT persistently exceeds twice the normal limit, the patient must be referred to a pediatric hepatologist [61].

Liver biopsy is the gold standard for diagnosis, but its invasiveness and the possible complications limit its use only to selected cases [61] (LOE VI-A).

Assessment of biochemical markers (i.e. retinol-binding protein 4, cytokeratine 18, hyaluronic acid) [62, 63] as indicators of hepatic histological damage, or clinical-laboratory scores as indicators of prognostic risk is not recommended in the clinical practice [64, 65] (LOEV-D).

Non-invasive investigations (magnetic resonance, computed tomography, elastography, ultrasound elastography) [66] are promising but again their use is not recommended. (LOE V-D).

NAFLD may be screened also in overweight children presenting with waist-to-height ratio > 0.5 and the assessment yearly repeated [67].

Gallstones

There is no evidence to recommend the screening for colelithiasis. LOE IV-C

Gallstone disease occurs in approximately 2% obese children and adolescents [68, 69]. The rate increases up to 5.9% in obese patients with rapid weight loss [70]. The disease is rarely diagnosed, since it is symptomatic only in 20% cases [69, 71] In the presence of pain, primarily in the right upper quadrant, nausea and vomiting, assessment of serum transaminases, gamma glutamil transpherase, alkaline phosphatase, bilirubin and liver ultrasonography are diagnostic [71,72,73].

Gastroesophageal reflux

Gastroesophageal reflux is suspected in the presence of evocative symptoms (such as pyrosis, heartburn, regurgitation). LOE VI-B

The prevalence of gastroesophageal reflux in obese children and adolescents is 13–25% (diagnosis made through questionnaires) [74,75,76,77,78]. Suggestive symptoms are pyrosis, epigastralgia, regurgitation. Weight loss may improve these symptoms. However, if symptoms persist or more severe symptoms occur (dysphagia, vomit) despite weight loss, referral for specialist investigations (gastrointestinal contrast study, endoscopy and oesophageal pH or impedance monitoring) and treatment is required [79].

Polycystic ovary syndrome

The components of the polycystic ovary syndrome should be considered in all female adolescents with obesity. LOE VI-A

Polycystic ovary syndrome (PCOS) is characterized by hyperandrogenism (acne, hirsutism and alopecia) and ovary dysfunction (oligo-amenorrhea). It is associated with increased risk of infertility, T2D, metabolic syndrome and cardiovascular disease in adulthood [80, 81]. In adult women, the diagnosis is based on at least two of the following criteria: a) oligo-ovulation and/or anovulation; b) clinical and/or biochemical signs of hyperandrogenism; c) polycystic ovary [82]. Since there is no widely accepted definition for PCOS in the teenage, it is suggested to identify and treat the single components of the syndrome [83]. Referral for specialist investigations is required to exclude other hyperandrogenic causes (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing syndrome/disease) [80,81,82,83,84].

Respiratory complications

Respiratory symptoms and signs should be sought in children and adolescents with obesity. LOE V-A

The prevalence of respiratory problems, such as asthma, obstructive sleep apnea syndrome (OSAS), and obesity hypoventilation syndrome (OHS) is higher in obese children and adolescents compared to the general population [85, 86]. OSAS affects 13–59% of obese children [85, 87,88,89]. The severity is strongly associated with excess weight, while adeno-tonsillar hypertrophy, skull-facial abnormalities, Afro-American and Asian ethnicities are modulation factors [85, 90]. The OHS is less frequent, affecting 3.9% obese patients [89].

Children and adolescents may present with increased breath rate, dyspnea after moderate efforts, wheezing, chest pain. OSAS is associated with intermittent hypoxemia, hypercapnia, and disrupted sleep. Specific symptoms and signs are: snoring/noisy breathing (> 3 nights/week), pauses in breathing, mouth breathing, awakening headache that may persist during the day, daytime sleepiness, inability to concentrate, poor academic performance, hyperactivity, cognitive deficits. Rarely, growth delay, systemic hypertension pulmonary and artery hypertension have been reported in severe obesity [91, 92].

OHS is characterized by severe obesity, chronic daytime alveolar hypoventilation (defined as PaCO2 levels > 45 mmHg and PaO2 < 70 mmHg), a pattern of combined obstruction and restriction, in absence of other pulmonary, neuromuscular, metabolic, or chest diseases that may justify daytime hypercapnia [89].

In the presence of respiratory symptoms/signs, transcutaneous saturation of O2 should be determined; for values < 95%, arterial blood emogasalysis should be performed. If asthma and/or any other ventilatory dysfunction are suspected, respiratory function (spirometry, pletismography, six minute walking test) should be measured. Allergological evaluation is not necessary, unless a history of atopia is reported [86], neither is necessary measuring the exhaled nitric oxide [93, 94]. Night polysomnography is the gold standard for diagnosis of sleep disorders. The apnea/hypopnea index (ratio between total number of apnea/hypopnea episodes and duration of sleep in hours) indicates the severity (1–5 very mild; 5–10 mild; 10–20 moderate;> 20 severe). Alternatively, overnight pulse oximetry can be used, which is very specific but less sensitive. Otorhinolaryngoiatric or odontoiatric evaluations complete the diagnostic work-up. Cardiology referral should be considered in severe and long-lasting OSAS for assessing lung or systemic hypertension, and left ventricular hypertrophy [91]. Cognitive assessement may be required to assess neurocognitive damage and behavioral disorders [95].

Orthopaedic complications

Orthopaedic complications should be sought in the presence of musculoskeletal pain and joint limit ation at the lower extremity. LOE V-A

Severity of obesity and sedentary lifestyle influence the morphology of osteo-cartilaginous structures and growth plate, leading to serious orthopedic consequences [96, 97]. The main orthopaedic complications are: slipped capital femoral epiphysis, Blount’s disease or tibia vara, valgus knee, flat foot [98,99,100,101,102,103].

Slipped capital femoral epiphysis may affect one or both hips; it usually occurs during the pubertal growth spurt. Hip pain and/or knee pain, an acute or insidious onset of a limp and decreased range of motion in the affected hip are the main symptoms/signs [104]. Blount disease is characterized by the varus deformity of the leg. Clinical manifestation is the instability of the knee in walking and lateral movements, simulating lameness [100]. Valgum knee is characterized by the deformity of the femoro-tibial angle in valgism; other deformities are associated, such as deviations in rotation of the tibia [101, 102]. Flat foot is characterized by flattening of the medial arch and heel valgus. Pain may be reported along the medial part of the foot, with more specific complaints after exercises or long walks [105].

Although obesity may exhibit higher risk of fracture, the measurement of bone density is not recommended. LOE V-D

The risk of fracture is increased in obese children, even for low energy injuries [106,107,108]. Inactivity, abnormalities in biomechanics of locomotion, inadequate balance may expose the obese child to fall and consequently to fracture, especially of the forearm [109]. There is no evidence that obesity results in a reduction of bone density [110]: while some studies have described an increased or normal bone mineral content, others reported a reduced bone mass in relation to bone size and weight [107].

Renal complications

There is insufficient evidence to recommend screening of kidney complications in non-diabetic and non-hypertensive children and adolescents with obesity. LOE IV-D

In adults, obesity is an independent risk factor for chronic kidney disease [111]. Obesity complication, (i.e. hypertension, dyslipidemia, insulin resistance, T2D, inflammatory state, autonomous system dysfunction) indeed, can alter the kidney function [112]. Peculiar to obesity, the obesity-related glomerulopathy is a secondary form of segmental focal glomerulosclerosis occurring tipically in obese patients and that improves after weight loss [112].

Obesity is likely to be a risk factor for chronic renal disease in children too. Indeed, children with renal disease have BMI higher than healthy population [113] and kidneys transplanted from obese donors have reduced glomerular filtration and higher rate of dysfunction than the kidneys obtained from normal weight donors [114]. In the light of current evidence [115,116,117,118,119], the assessment of microalbuminuria is not recommended in non-diabetic and non-hypertensive obese children (LOE IV-D). Individual cases of severe obesity (BMI > 40) that may be associated with proteinuria in the nephrotic range remain to be evaluated individually (LOE VI-C).

Idiopathic endocranic hypertension

Headache, vomiting, photophobia, transiently blurred vision, diplopia should be sought in subjects with overweight/obesity, especially if adolescents. LOE V-A

Idiopathic endocranial hypertension is rare but potentially serious condition that can cause permanent loss of vision [120,121,122]. Prevalence and risk of recurrence increase with the severity of BMI [123,124,125]. Some symptoms occur frequently in adolescents as in adults (headache, vomiting, photophobia, transiently blurred vision, diplopia), while irritability, apathy, drowsiness, dizziness, cervical and dorsal pain are less frequent [123, 126]. The diagnosis is based on the presence of increased intracranial pressure documented with a lumbar puncture, papilledema, normal neurologic examination results (except for cranial nerves), normal cerebrospinal fluid composition, normal appearance of neuroimaging studies, and no other identifiable cause of increased intracranial pressure [127].

Migraine and chronic headache

Promoting healthy lifestyle habits and weight control can be a protective factor of migraine and chronic headache. LOE V-B

Recent studies have reported greater risk of episodic or recurrent migraine or daily chronic headache or tension headache in obese children and adolescents than the normal population [128, 129]. Some drugs used for headache and migraine have weight gain as side effect [129]. Negative lifestyle factors, which may influence the prevalence of recurrent headache, are possible targets for preventive measures [130]. An intervention study reported improvement in migraine symptoms after weight loss [131].

Psychosocial correlates

Psychosocial discomfort may affect therapeutic success, therefore it should be identified as part of the multi-disciplinary assessment. LOE V-A

Recognition of psycho-social correlates (unsatisfactory body image, depressive and anxiety symptoms, loss of eating control, weight concern, dysfunctional social relationships, inactivity due to problematic body image, obesity-related stigma, low self-esteem, academic failure) is crucial to promoting specific strategies that improve the results in weight loss programs [132,133,134]. Although obesity is not a psychopathological and behavioral disorder, referral for specialist consult is needed in the suspicious of depressive and/or anxious symptoms, dysmorphophobic traits, suicidal risk, and eating disorders [135, 136].

Binge eating disorder

The presence of binge eating disorder should be considered in the multi-professional assessment of an obese child or adolescent. LOE V-B

Binge Eating Disorder (BED) is the most common Nutrition and Eating Disorder found in pediatric obesity. It is indicative of psychopathology and is a serious risk factor for the development of obesity, especially in the presence of family history of obesity and marked negative experiences coupled with factors predisposing to psychiatric disorders [137]. BED is often preceeded by uncontrolled eating since childhood, occasional bulimia, obesity, but also by an attention deficit and hyperactivity disorder [136,137,138]. Upon referral to appropriate medical subspecialists and/or mental health personnel, the diagnosis of BED is critical to the therapeutic success. It may be necessary associating psychological and pharmacological therapy (only in selected cases) within the weight-loss treatment program [136, 137, 139].

Treatment

Changes in diet and lifestyle leading to a negative caloric balance is recommended to gradually reduce the BMI. LOE I-A

The main objective is a permanent change in the child’s eating habits and lifestyle, rather than attaining rapid weight loss through low-calorie diets. It is indispensable involving the whole family and setting realistic goals.

Further goals:

  • maintaining an appropriate growth rate and achieving an healthier weight-to-height ratio;

  • reducing weight excess (without necessarily achieving the ideal weight), in particular the fat mass, while preserving the lean mass;

  • maintaining or promoting good mental health (self-esteem, correct attitudes toward food and body image, health related quality of life);

  • treatment and improvement/resolution of complications, if present, in the shortest time possible;

  • achieving and mantaining a healthier weight-to-height ratio and preventing relapses.

Diet

A balanced and varied diet is recommended (LOE I-A)

The classic diet-therapy based on the prescription of a low calorie diet is not effective in the medium/long term with relapses and failures, increased risk of dropout and progression into more complicated forms [140] (LOE III-B).

The educational process starts from the assessment of the child’s and family’s dietary habits, by means of the assessment of meal composition, portions, frequency of food intake, food preferences or aversions, use of condiments, cooking methods and food presentation [141,142,143,144,145] (LOE I-A).

Food diary is an excellent tool for assessing eating behavior; it should be compiled by the child together with the parents or by the adolescent and evaluated by the operator [146, 147] (LOE I-B).

Dietary advice

  1. 1.

    Eat 5 meals a day (three meals and no more than two snacks) [148] (LOE V-B)

  2. 2.

    Have an adequate breakfast [149] (LOE II-B)

  3. 3.

    Avoid eating between meals [150] (LOE III-B)

  4. 4.

    Avoid high-energy and low nutrient density foods (eg. sweetened or energizing drinks, fruit juices, fast food, high-energy snack) [151, 152] (LOE III-B)

  5. 5.

    Increase intake of fruit, vegetables and fiber rich cereals [153, 154] (LOE VI-A)

  6. 6.

    Limit portions [155, 156] (LOE I-A)

If a hypocaloric diet is needed, it should fulfill the National Recommended Energy and Nutrient Intake Levels, based on sex, age and ideal weight for stature (proteins 1 g/kg/day; carbohydrates 45–60% of total calories; simple sugars < 15% of total calories, lipids 20–35% of total calories starting from 4 years of age, saturated fatty acids < 10% of total calories) [157] (LOE VI-A).

Efficacy of dietary regimens

There are currently no randomized controlled trials (RCTs) examining the effects of different diets on child’s weight and body composition, regardless of potential confounders such as treatment intensity, behavioral or physical activity strategies [158, 159].

Very low caloric diet

It is the most effective regimen in terms of weight loss [160]. One example is the protein-sparing modified fast (600–800 kcal/day, protein 1.5–2 g/kg ideal weight, carbohydrates 20–25 g/day, multivitamins + minerals, water > 2000 ml/day), which can be prescribed in selected patients with severe obesity, under close medical surveillance and in specialized pediatric centers. The aim is to induce rapid weight loss (duration of this restrictive diet no longer than 10 weeks) followed by a less restrictive diet regimen balanced in macronutrients. RCTs are not available to evaluate medium to long-term efficacy compared to other diet-therapies and possible adverse effects on growth (LOE III-C).

Traffic light and modified traffic light diets

Reduced caloric intake (1000–1500 kcal/day) is achieved trough categories of foods grouped by nutrient density [161]. They were found to produce a significant improvement of BMI in 8–12 year old children even in the long term [162] (LOE III-C).

Non-restrictive approach

It does not consider a given caloric intake or nutrient composition, rather it focuses on the consumption of low-fat and high-nutrient density foods (LOE III-C).

Replacement meals

They are not recommended, since efficacy and safety have not been tested in children/adolescents.

No significant effect has been demonstrated for diets with specific macronutrient composition and medium caloric content in children. In particular:

Hypocaloric diets with low glycemic index and low glycemic load

Although an effect on satiety is suggested, their superiority compared with other dietary approaches has not been proved over the medium term [163,164,165] (LOE I-C).

Exercise

It is recommended to associate physical exercise to diet. LOE I-A

Physical exercise ameliorates body composition and reduces cardio-metabolic risk factors. [166,167,168,169,170,171]. Change in body composition (in particular fat reduction) rather than reduced BMI is sensitive to evaluating the effectiveness of exercise [166, 172].

It has not yet been proven which is the ideal exercise for obese children [170]. Low evidence demonstrates that combining aerobic and resistance exercises results in fat mass reduction, especially with programs of at least 2 weekly sessions and duration > 60 min [173] (LOE I-B).

The evidence is limited that exercising at higher intensity is more effective in modifying the body composition (LOE I-B).

Owing to difficulty of obese subjects to practice exercise at high intensity, there is no evidence that vigorus efforts result in greater body fat reduction [166]. Children and adolescents should practice 60 min or more of physical activity every day, which should be mainly represented by aerobic exercises at least of moderate intensity; resistance exercises are suggested for at least 3 times a week, adjusted to the physical abilities of the obese child [174, 175]. Examples of aerobic and resistance exercises for obese children and adolescents are synthetized in Table 6. The practice of recreational activities and sports that involve a large amount of body mass such as swimming, soccer, basketball, volleyball, handball, rugby or require anaerobic and neuromuscular power, such as gymnastics or judo is encouraged. In severe obesity exercises that put constant weight or repeated impact on the child’s legs, feet and hips should be avoided.

Table 6 Examples of aerobic and resistance exercises suggested for obese children and adolescents

Sedentary behaviors

It is suggested to reduce the time spent in sedentary behaviours (television viewing, videogaming, internet surfing). LOE II-B

Weight gain may be only partially due to sedentary behaviors [176,177,178,179]; in the case of television viewing, it may be associated with overfeeding [180]. Interventions targeting sedentary behaviour were more effective in children aged 5–12 years [181].

Use of active video games may be suggested to increase daily energy expenditure in obese and sedentary children. LOE I-B

Active video games represent an additional strategy to reduce sedentary behaviors. They do not replace ‘real’ sports activities, but can contribute to increase energy expenditure beyond the sedentary activity threshold, provided they are supervised by adults [182,183,184,185,186,187].

The systematic use of active video games for weight loss and improvement of body composition is not discouraged. LOE III-C

While studies are not consistent with the recommendation to use active video games to obtain weight loss or improve body composition, their use is not recommended but neither discouraged to obtain other effects (improvement in vascular response, heart rate and VO2max or obesity-related comorbidities; positive psycho-behavioral and psycho-social effects) [182,183,184].

Cognitive and family-based behavioral therapy

Cognitive behavioral treatment or family-based behavioral treatment are both recommended to favor better adhesion to diet and physical activity. Cognitive behavioral treatment LOE III- B; family-based behavioral treatment LOE I- A

Cognitive behavioral techniques are effective. Neverthless, they are not easily applicable requiring specific training of the multidisciplinary team [188,189,190]. The most effective techniques are goal setting, self-monitoring (through food and physical activity diaries), contingency training, stimulus control, positive reinforcement, cognitive restructuring, problem solving [191].

Family-based behavioral treatments involve multi-component interventions aimed at changing the lifestyle of the whole family, with goals shared between parents and children [191,192,193,194]. Interventions in which parents are active participants are more effective than interventions in which they are not encouraged to make their own behavioral changes. On the other hand, family-based therapies require greater investment of resources in terms of time and staff involved [188, 190, 192,193,194,195,196,197,198]. In children, they are more effective than treatments not involving parents. There is no robust evidence demontsrating their superiority in adolescents [189, 190, 194] (LOE I-A).

Therapeutic education has been proposed in the recent years, using tools of cognitive-behavioral approach and motivational interview, such as reflective listening, therapeutic alliance, family approach, modeling, motivational counseling, narrative approach, positive reinforcement, goal setting, negotiating treatment objectives. It requires professional skills of all the team members with ongoing training [199,200,201] (LOE VI-B).

Child Appetite Awareness Training and Cue Exposure Treatment are still considered experimental and require further studies [202, 203] (LOE V-C).

Indicators of successful treatment

The BMI standard deviation score is recommended to estimate weight loss. LOE V-B

The reduction of the BMI Standard Deviation Score (BMI-SDS) is the best indicator of the weight loss amount taking into account the patient’s age and gender [204]. A reduction > 0.5, but even > 0.25 (consistent with a 1 kg/m2 BMI reduction or stable weight for more than 1 year in a growing child) was associated with improved body composition and decreased cardio-metabolic risk [205].

Waist circumference and waist/height ratio can be used to monitor abdominal fat variations but are subject to error and offer no benefit over BMI [204, 206,207,208]. The same is true for the skinfold thicknesses [204, 209].

Other behavioral indicators (related to diet, lifestyle, physical fitness or quality of life) can be considered if no substantial reduction in the BMI-SDS occurs. LOE VI-B

Since the percentage of weight loss is generally low, evaluation based solely on the BMI-SDS may induce a sense of failure in the family and healthcare workers. In order to maintain the adherence to treatment, a stable modification of diet, physical activity and sedentary behavior, the increase of physical fitness and improvement of the quality of life should be considered as index of good compliance [210, 211].

The scarce effect of treatment in the long term demands the development of long-lasting care models and their validation. LOE VI-B

The effectiveness of treatment programs based on diet and lifestyle on BMI-SDS reduction was shown only in the short term (6–12 months) [167, 212]. In a European multicentre study, the success rate (BMI SDS reduction > 0.25) was 7% at 2 years; it reached 50% in a few number of centers, which differed for the greater intensity of intervention and training of the multi-disciplinary team [213, 214]. Only two national studies based on diet education, cognitive or cognitive-behavioral strategies and family involvement reported BMI-SDS reduction of 0.44 after three years [199] and 1.49 after 5 years of follow up [188], respectively.

It is necessary to monitor the possible onset of eating disorders, especially when the weight loss is rapid. LOE IV-A

Dissatisfaction with body image may be related to the onset of eating disorders, especially bulimia nervosa and binge eating, but also of anorexia nervosa [215,216,217,218]. Diet education undertakings can accentuate the perceived stigma in subjects with obesity, causing drastic strategies of weight control [219, 220]. In some cases, the onset is triggered by an initially desired restriction of food, which then becomes uncontrollable. Careful evaluation of excessive weight variations and related bodily experience, especially when hypocaloric diets are prescribed, is recommended [217,218,219, 221].

Pharmacological intervention

Pharmacological therapy can only be applied after the failure of the multidisciplinary lifestyle intervention. LOE VI-B

When clinically significant weight loss cannot be achieved through lifestyle-based interventions, use of drugs is considered, especially in severe obesity with cardiometabolic, hepatic or respiratory disorders [222,223,224,225,226]. Management of drugs should be done in specialist centers [225].

Orlistat is the only drug available for the treatment of children and adolescents with severe obesity age. LOE II-B

Few studies, with small sample size and short duration, are available on the effects of anti-obesity medications in pediatric age [227,228,229,230]. Orlistat (tetra-hydro-lipstinate) is the only drug approved for the treatment of obesity in pediatric age. It seems producing significant weight loss and favoring behavioral changes [231,232,233]. It does not affect the mineral balance, if the low-calorie diet is associated with normal mineral content; on the contrary, attention must be paid to prevent liposoluble vitamins deficiency [234].

Bariatric surgery

Bariatric surgery is the ultimate solution in adolescents with severe obesity and resistant to all other treatments, especially when serious complications are present. LOE VI-B

The indications for surgery in the adolescent are (LOE III-B) [235, 236]:

  • BMI ≥35 kg/m2 with at least one severe comorbidity, such as T2D, moderate to severe obstructive sleep apnea (AHI > 15), idiopathic endocranial hypertension, NAFLD with significant fibrosis (Ishak score > 1).

  • BMI ≥40 kg/m2 with less serious comorbidities, such as mild sleep apnea (apnea/hypopnea index > 5), hypertension, dyslipidemia, carbohydrate intolerance.

More prudently other guidelines suggest a BMI > 40 kg/m2 with one severe comorbidity or > 50 kg/m2 with less serious comorbidities [223, 237].

Eligibility criteria are: adolescents with long lasting severe obesity; a. previous failure of any dietetic, behavioral or pharmacological intervention (after at least 12 months of intensive treatment); b. family and social support in managing the multidisciplinary care programs; c. decisional capacity for surgical management and the post-surgery follow-up; d. able to express the informed assent.

Surgery should be performed in a highly specialized center that guarantees the presence of an experienced multidisciplinary team. LOE III-A

The multidisciplinary team carefully evaluates the case and poses the indication for the surgey taking care of the pre-surgical assessment and post-surgical follow-up [238, 239]. The preoperative phase includes a comprehensive assessment of the patient and the family, with particular regard to physical and psychological maturation of the adolescent and his/her adherence to treatment [235, 237, 240]. Neuropsychiatric counseling should be undertaken to identify cases at risk of psychotic disorders, severe major depression, personality or eating disorders, alcoholism and drug dependence [235,236,237]. In the postoperative follow-up anthropometric, clinical and nutritional assessment, and counseling are performed and early or late complications are monitored.

For the adverse effect on height velocity, the adolescent should have reached adequate skeletal maturation or a pubertal stage IV according to Tanner [223, 236, 237, 241] (LOE III-A).

Contraindications to surgery are documented substance abuse problem and/or drug dependencies; patient inability to care for him/herself or to participate in life-long medical follow-up, no long-term family or social support that will warrant such care and follow-up; acute or chronic diseases even not directly associated with obesity threatening life in the short term; high anesthetic risk; pregnancy or planned pregnancy within the first two years after surgery, current breast-feeding [237] (LOE VI-A).

Indication for surgery must be given on a case-by-case basis by the multidisciplinary team (LOE VI-A)

Surgical procedures performed mostly by laparoscopy in adolescents and supported by at least 3 years of follow-up, are: a. restrictive interventions, including adjustable gastric bandage and sleeve gastrectomy; b. restrictive/malabsorbitive interventions, such as Roux-en Y gastric by-pass (RYGB) (LOE III-B).

Although the RYGB is the gold standard, there is no enough evidence to support this specific surgical technique compared to the others in terms of effectiveness, side effects, long-term complications and benefits [239]. Although studies in adolescents have increased, lack of RCTs makes it difficult to establish the effective efficacy at this age. There is no evidence or expert opinion supporting the efficacy of anticipating bariatric surgery to the teenage with respect to adults. A recent Cochrane review identified four RCTs in progress with expected results in the near future [242]. Several non-randomized and non-controlled trials were published with at least three years follow-up on the use of bariatric surgery in adolescents [243,244,245,246,247]. The published studies showed an average BMI decrease of 16.6 kg/m2 after RYGB, 11.6 kg/m2 after gastric bandage and 14.1 kg/m2 after sleeve gastrectomy [248]. All interventions have been associated with improvement or complete restoration of comorbidities. Most studies are consistent in demonstrating improvement of the quality of life [244, 248,249,250].

Care settings

For the multifactorial nature of obesity, variability in its severity, and the health implications, treatment should be conducted in multiple settings with different levels of treatment. LOE III-A

Health services should be organized in a network of services [150, 251,252,253,254]. Fundamental is the periodic training of all network operators on motivational counseling, parenting and teamwork [251]. A child- and family-centered approach is based on sharing simple and realistic objectives about ​​eating habits, sedentary behaviours, physical activity, and verification of results related to improving nutritional status, quality of life and complications if present [255,256,257,258].

Primary care pediatricians represent the first level treatment. LOE III-A

Primary care pediatricians’ responsibilities are summarized in Table 7 [259, 260]. They are the reference point for obese children/adolescents and their family, participating in the various proposals for action and decisions, when a more aggressive approach is proposed (e.g., hospitalization or surgery). The efficacy of obesity treatment in the primary care setting is still modest [261, 262], but it might improve if pediatricians are assisted by other professionals experienced in pediatric obesity (dieticians/nutritionist, psychologist) and trained in family education and interdisciplinary work [258, 259, 263, 264] (LOE VI-B).

Table 7 Primary care pediatricians’ responsibilities

District or hospital outpatient services represent the second level of care. LOE VI-A

In the second level centers, the multidisciplinary team (pediatrician, dietician and psychologist) experienced in pediatric obesity defines the clinical condition of children referred by the primary care pediatricians, and runs the multidisciplinary intervention that is centered on diet education and lifestyle modification [150, 260, 265, 266]. The patient is referred to the third level health care center in case of no response to the treatment, severe comorbidities, compromised psychological balance or significantly impaired quality of life.

Specialized centers for pediatric obesity represent the third level of care. LOE VI-A

Third level centers are organized on a multidisciplinary and multiprofessional basis for comorbidity management or bariatric surgery. They admit patients who are suspected of secondary obesity or require more specialistic diagnostic assessment and/or intensive care programs, including bariatric surgery. They coordinate the networking activities as well as the training of operators and promote research activities and intervention trials in the context of specific protocols [267,268,269,270,271].

Transition

Pediatric obesity care should include a transition path from pediatric to adult care. LOE VI-B

It is necessary to test a transition model for adolescents with severe obesity and/or complications, particularly with metabolic syndrome, NAFLD, hypertension [272,273,274]. Unfortunately, the experience is extremely limited for the high drop-out, poor consideration about obesity as chronic illness, absence of pre-established pathways, possible transition to structures that follow the specific complications (eg. hypertension), no availability of cost-effective models [275].

Prevention

Given the multifactorial nature of obesity, preventive interventions should be designed to modify the environmental and social determinants. Health and non-health professionals should be involved in implementing healthy food education and promoting physical activity. Promotion of balanced nutrition and healthy lifestyle implies the need to remodel economic, agricultural, industrial, environmental, socio-educational, recreational and health policies, including those aimed at contrasting socio-economic and ethnic minorities’ inequalities [276]. To be effective, actions must be multicomponent and multilevel, building agreements and alliances among many stakeholders, including families, community organizations such as schools and sport institutions, health care providers [277,278,279]. Primary prevention actions begin from the prenatal age, involving the “Birth Pathway” within the family counselling services, spanning to the adolescence with actions spread at individual, family and community levels [260].

Prevention is based on behavioral modification starting from the prenatal age. LOE I-A

Lifestyle-based interventions are able to achieve mild but significant effects on dysfunctional behaviors (diet, physical activity, sedentary behaviours) and BMI [280]. Maintaining the BMI in a growing child is an important health objective. The best results have been obtained in school settings and in children 6–12 years [263]. Further studies are needed to determine the effectiveness of preventive interventions in children under 3 years and adolescents [281].

The family involvement is strongly recommended. LOE III-A

Similarly to treatment, preventive interventions involving the whole family are recommended as more successful and long lasting compared to child-centered interventions, though they were more effective in children than adolescents [263, 282,283,284]. Interventions targeting at specific behaviors, such as taking fruits and vegetables and reducing sedentary behaviours have been found effective as well [283].

Prenatal age

Women should start pregnancy with appropriate weight and control their weight gain following an healthy lifestyle. LOE III-A

An excessive weight gain during pregnancy is associated with fetal macrosomy and increased risk of obesity [285,286,287,288,289,290]. This effect is independent of maternal hyperglycemia, which is also a well-known risk factor for future obesity [291]. Recommended gestational weigh gain is between 11.5 and 16 Kg in normal weight women, 7 to 11.5 Kg, in overweight and 5 to 9 Kg in those who with prepregnancy obesity [292].

Tobacco smoke in pregnancy is banned. LOE III-A

Maternal smoking in the perinatal age increased the risk of overweight at age 7 regardless of birth weight; the risk increased for maternal smoking not only in pregnancy but also in the post-natal period. There was a dose-dependent effect. Hence, smoking exposure must be banned in pre- and post-natal life [293, 294].

Diet

First two years of life

Avoid excessive weight gain and/or increased weight-to-length ratio from the very first months of life. LOE III-A

Early rapid weight gain increases the risk of overweight and obesity in childhood [295]. Prevention in infants is focused on quality, quantity and timing of food intake. In particular:

Exclusive breastfeeding is recommended up to 6 months [296,297,298,299]. LOE III-A.

Solid foods and beverages other than breast milk or infant formulas should be introduced no earlier than 4 months and no later than 6 months [300,301,302,303,304,305]. LOE III-B.

Protein intake should be limited to less than 15% of the daily energy intake [302, 306,307,308,309]. LOE I-B.

Reduction of lipid intake to percentages indicated for adults is not recommended [310]. LOE II-D.

Sweetened drinks should be avoided [311]. LOE III-A.

There is insufficient evidence that complementary responsive feeding practices, such as baby-led weaning (which is associated with early satiety-responsiveness acquisition), are protective against obesity respect to usual complementary feeding mode [312,313,314]. LOE V-C.

From preschool age to adolescence

Low energy density diet is recommended, based on the principles of the Mediterranean diet, promoting at least 5 servings of fruit and vegetables and plant based proteins [315]. Food should be distributed in no more than 5 daily meals and household consumption of meals should be promoted [316, 317]. LOE V-A.

The use of fast food and fast food-based venues should be limited [318, 319].LOE V-A.

Avoid sweetened drinks, including sports drinks and juice additives; alcoholic and energy drinks should also be avoided in adolescents [320,321,322]. LOE I-A.

Physical activity

It is recommended that children/adolescents spend on average 60 min a day on moderate/vigorous physical activity. LOE III-A

Prospective studies have shown a negative association between levels of physical activity and overweight/obesity [323, 324]. Even moderate physical activity is sufficient to improve aerobic fitness, an important marker of metabolic health which is independent of adiposity [325, 326]. 210, 211 Moderate physical activity is more effective and easier to implement in children who are sedentary or overweight. The increase of physical activity levels can be achieved starting from the age of 2–3 years by active play, walking, using the tricycle, and after 5–6 years, promoting also sports participation 2/3 times a week. Exercise should primarily stimulate aerobic capacity, but also strength and flexibility, be adequate to the child’s ability and stage of physical and psychomotor development [174, 175, 327].

Sedentary behaviours

The use of television and electronic games is discouraged in children < 2 years of age. LOE VI-B

Although there are no specific studies on the effects of video exposure on overweight/obesity in this age group, video exposure should be discouraged since it may disturb sleep regularity [328, 329].

Sedentary behavior, especially the time spent in front of a screen (TV, video games, computers, mobile phones, etc.) should be reduced to less than 2 h a day in children > 2 years of age. LOE III-B

The association between sedentary behaviour, obesity and cardiometabolic risk factors is weak, and it is reduced when corrected for physical activity levels [330]. On the contrary, the evidence based on prospective studies and RCTs show a strong relationship between television hours, obesity and cardio-metabolic risk factors, presumably because overfeeding frequently occurs [331, 332].

Several studies demonstrated a greater amount of television hours in children who have a television in their bedroom, but there is no clear evidence that its removal reduces the duration of the video exposure [333]; on the contrary the installation of an electronic television time manager seems effective [334]. Decreasing sedentary behavior was more successful in reducing BMI in children 5–12 years [181]. Prospective studies showed that interrupting prolonged sedentary periods with mild physical activity had beneficial effects on metabolic outcomes in adults [335]. Although evidence is lacking in pediatric age, it is suggested breaking up prolonged sitting time at home and school.

Sleep duration and quality

Adequate sleep duration and quality should be promoted in infants, children and adolescents. LOE III-B

A short sleep duration is a potential risk factor for overweight/obesity through neuroendocrine and metabolic influences [336, 337]. One meta-analysis of longitudinal studies indicated a risk of obesity more than doubled in children with a sleep duration lower than recommended [338]. Three intervention studies aimed at changing sleeping hours within a multicomponent obesity treatment were not effective in reducing the BMI [339]. Waiting for stronger evidence, we endorse the recommendation for optimal amount of sleep in children and adolescents released by the American Academy of Sleep Medicine [340] syntethized in Table 8. Turning off all “screens” 30 min before bedtime is also suggested to ensuring adequate sleep.

Table 8 Recommended amount of sleep in children and adolescents

Involvement of school settings for implementing preventive actions

It is recommended to include the school settings in obesity prevention programs. LOE I-A

The school is institutionally devoted to the education of children and is certainly a privileged area for the implementation of preventive actions. Studies support with moderate/high evidence that promoting healthy nutrition and physical activity at school prevent excessive weight gain and reduce the prevalence of overweight/obesity [341, 342]. The most effective and promising changes are summarized in Table 9. [334].

Table 9 Effective environmental strategies to prevent pediatric obesity at school

Conclusions

This paper is a Consensus position document on the care of pediatric obesity in children and adolescents produced by experts belonging to the Italian Society for Pediatric Endocrinology and Diabetology and the Italian Society of Pediatrics, and endorsed by the main Italian scientific societies involved in tackling obesity and its complications.

Consistent evidences suggest that the disease-burden of obesity on the overall health starts very early in life and is particularly serious for the development of cardiometabolic disease risk factors during childhood and adolescence and the association with premature mortality in adults. Furthermore, the mechanical and psychosocial comorbidities undermine physical functioning and the health-related quality of life. Several systematic reviews and meta-analyses on treatment and prevention indicate that weight control may be obtained by multicomponent intervention focused on a life-long change in the child’s eating habits and lifestyle, involving the whole family and the surrounding social environment (school, communities). The effectiveness of treatment programs based on diet and lifestyle on excess weight reduction was shown only in the short term. Further study is needed to evaluate the effectiveness and safety of the different modalities of treatment, including pharmacotherapy and/or bariatric surgery, in the long term.

Abbreviations

BED:

Binge eating disorder

BMI:

Body mass index

BP:

Blood pressure

DBP:

Diastolic blood pressure

HbA1c:

Hemoglobin glycosilated A1c

HDL-C:

HDL-cholesterol

IGT:

Impaired glucose tolerance

LOE:

Level of evidence

NAFLD:

Non-alcoholic fatty liver disease

OGTT:

Oral glucose tolerance test

OHS:

Obesity hypoventilation syndrome

OSAS:

Obstructive sleep apnea syndrome

PCOS:

Polycystic ovary syndrome

RCTs:

Randomized controlled trials

RYGB:

Roux-en Y gastric by-pass

SBP:

Systolic blood pressure

SDS:

Standard deviation score

T2D:

Type 2 diabetes

TG:

Triglycerides

WHO:

World Health Organization

References

  1. 1.

    Spinelli A, Nardone P, Buoncristiano M, Lauria L, Pierannunzio D. Centro nazionale per la prevenzione delle malattie e la promozione della salute, Cnapps-Iss. OKkio alla Salute: i dati nazionali. 2016; http://www.epicentro.iss.it/okkioallasalute/dati2016.asp

  2. 2.

    Valerio G, Licenziati MR, Manco M, et al. Health consequences of obesity in children and adolescents. Minerva Pediatr. 2014;66:381–414.

  3. 3.

    Società Italiana di Pediatria Obesità del bambino e dell’adolescente: Consensus su prevenzione, diagnosi e terapia. Argomenti di Pediatria 1/06. Milano: Istituto Scotti Bassani; 2006.

  4. 4.

    Programma nazionale Linee Guida Manuale metodologico. Come produrre, diffondere e aggiornare raccomandazioni per la pratica clinica. Maggio. 2002. http://old.iss.it/binary/lgmr2/cont/Manuale_PNLG.1234439852.pdf.

  5. 5.

    WHO Multicentre Growth Reference Study Group. WHO child growth standards based on length/height, weight and age. Acta Paediatr Suppl. 2006;450:76–85.

  6. 6.

    de Onis M, Onyango AW, Borghi E, Siyam A, Nishida C, Siekmann J. Development of a WHO growth reference for school-aged children and adolescents. Bull WHO. 2007;85:660–7.

  7. 7.

    Cacciari E, Milani S, Balsamo A, et al. Italian cross-sectional growth charts for height, weight and BMI (2 to 20 yr). J Endocrinol Investig. 2006;29:581–93.

  8. 8.

    Valerio G, Balsamo A, Baroni MG, et al. Childhood obesity classification systems and cardiometabolic risk factors: a comparison of the Italian, World Health Organization and international obesity task force references. It J Pediatr. 2017;43(Suppl 1):19.

  9. 9.

    Barlow SE, Expert Committee. Recommendations regarding the prevention, assessment and treatment of child and adolescent overweight and obesity: summary report. Pediatrics. 2007;120(Suppl 4):S164–92.

  10. 10.

    de Onis M, Lobstein T. Defining obesity risk status in the general childhood population: which cut-offs should we use? Int J Pediatr Obes. 2010;5:458–60.

  11. 11.

    de Onis M, Martínez-Costa C, Núñez F, Nguefack-Tsague G, Montal A, Brines J. Association between WHO cut-offs for childhood overweight and obesity and cardiometabolic risk. Public Health Nutr. 2013;16:625–30.

  12. 12.

    Kelly AS, Barlow SE, Rao G, Inge TH, Hayman LL, Steinberger J, Urbina EM, Ewing LJ, Daniels SR, American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young, Council on Nutrition, Physical Activity and Metabolism, and Council on Clinical Cardiology. Severe obesity in children and adolescents: identification, associated health risks, and treatment approaches: a scientific statement from the American Heart Association. Circulation. 2013;128:1689–712.

  13. 13.

    Martos-Moreno GÁ, Barrios V, Muñoz-Calvo MT, Pozo J, Chowen JA, Argente J. Principles and pitfalls in the differential diagnosis and management of childhood obesities. Adv Nutr. 2014;5:299S–305S.

  14. 14.

    Mason K, Page L, Balikcioglu PG. Screening for hormonal, monogenic, and syndromic disorders in obese infants and children. Pediatr Ann. 2014;43:e218–24.

  15. 15.

    Angulo MA, Butler MG, Cataletto ME. Prader-Willi syndrome: a review of clinical, genetic, and endocrine findings. J Endocrinol Investig. 2015;38:1249–63.

  16. 16.

    Khan SA, Muhammad N, Khan MA, Kamal A, Rehman ZU, Khan S. Genetics of human Bardet–Biedl syndrome, an updates. Clin Genet. 2016;90:3–15.

  17. 17.

    Marshall JD, Muller J, Collin GB, et al. Alström syndrome: mutation spectrum of ALMS1. Hum Mutat. 2015;36:660–8.

  18. 18.

    Douzgou S, Petersen MB. Clinical variability of genetic isolates of Cohen syndrome. Clin Genet. 2011;79:501–6.

  19. 19.

    Mangelsdorf M, Chevrier E, Mustonen A, Picketts DJ. Börjeson-Forssman-Lehmann syndrome due to a novel plant homeodomain zinc finger mutation in the PHF6 gene. J Child Neurol. 2009;24:610–4.

  20. 20.

    Twigg SR, Lloyd D, Jenkins D, et al. Mutations in multidomain protein MEGF8 identify a carpenter syndrome subtype associated with defective lateralization. Am J Hum Genet. 2012;91:897–905.

  21. 21.

    Basil JS, Santoro SL, Martin LJ, Healy KW, Chini BA, Saal HM. Retrospective study of obesity in children with Down syndrome. J Pediatr. 2016;173:143–8.

  22. 22.

    Bojesen A, Kristensen K, Birkebaek NH, et al. The metabolic syndrome is frequent in Klinefelter's syndrome and is associated with abdominal obesity and hypogonadism. Diabetes Care. 2006;29:1591–8.

  23. 23.

    Calcaterra V, Brambilla P, Maffè GC, et al. Metabolic syndrome in turner syndrome and relation between body composition and clinical, genetic, and ultrasonographic characteristics. Metab Syndr Relat Disord. 2014;12:159–64.

  24. 24.

    Albuquerque D, Stice E, Rodríguez-López R, Manco L, Nóbrega C. Current review of genetics of human obesity: from molecular mechanisms to an evolutionary perspective. Mol Gen Genomics. 2015;290:1191–21.

  25. 25.

    Huvenne H, Dubern B, Clément K, Poitou C. Rare genetic forms of obesity: clinical approach and current treatments in 2016. Obes Facts. 2016;9:158–73.

  26. 26.

    Genovesi S, Antolini L, Giussani M, et al. Hypertension, prehypertension, and transient elevated blood pressure in children: association with weight excess and waist circumference. Am J Hypertens. 2010;23:756–61.

  27. 27.

    Friedemann C, Heneghan C, Mahtani K, Thompson M, Perera R, Ward AM. Cardiovascular disease risk in healthy children and its association with body mass index: systematic review and meta-analysis. BMJ. 2012;345:e4759.

  28. 28.

    Lo JC, Chandra M, Sinaiko A, et al. Severe obesity in children: prevalence, persistence and relation to hypertension. Int J Pediatr Endocrinol. 2014;2014:3.

  29. 29.

    Rosner B, Cook NR, Daniels S, Falkner B. Childhood blood pressure trends and risk factors for high blood pressure: the NHANES experience 1988-2008. Hypertension. 2013;62:247–54.

  30. 30.

    Wirix AJ, Nauta J, Groothoff JW, et al. Is the prevalence of hypertension in overweight children overestimated? Arch Dis Child. 2016;101:998–1003.

  31. 31.

    Strambi M, Giussani M, Ambruzzi MA, et al. Novelty in hypertension in children and adolescents: focus on hypertension during the first year of life, use and interpretation of ambulatory blood pressure monitoring, role of physical activity in prevention and treatment, simple carbohydrates and uric acid as risk factors. Ital J Pediatr. 2016;42:69.

  32. 32.

    National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114:555–76.

  33. 33.

    Lurbe E, Agabiti-Rosei E, Cruickshank JK, et al. European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. J Hypertens. 2016;34:1887–920.

  34. 34.

    Spagnolo A, Giussani M, Ambruzzi AM, et al. Focus on prevention, diagnosis and treatment of hypertension in children and adolescents. Ital J Pediatr. 2013;39:20.

  35. 35.

    Estrada E, Eneli I, Hampl S, et al. Children’s hospital association consensus statements for comorbidities of childhood obesity. Child Obes. 2014;10:304–17.

  36. 36.

    Di Bonito P, Moio N, Sibilio G, et al. Cardiometabolic phenotype in children with obesity. J Pediatr. 2014;165:1184–9.

  37. 37.

    Pieruzzi F, Antolini L, Salerno FR, et al. The role of blood pressure, body weight and fat distribution on left ventricular mass, diastolic function and cardiac geometry in children. J Hypertens. 2015;33:1182–92.

  38. 38.

    American Diabetes Association. Classification and diagnosis of diabetes. Sec. 2. In standards of medical Care in Diabetes-2016. Diabetes Care. 2016;39(Suppl. 1):S13–22.

  39. 39.

    Zhang X, Gregg EW, Williamson DF, et al. A1C level and future risk of diabetes: a systematic review. Diabetes Care. 2010;33:1665–73.

  40. 40.

    Kester LM, Hey H, Hannon TS. Using hemoglobin A1c for prediabetes and diabetes diagnosis in adolescents: can adult recommendations be upheld for pediatric use? J Adolesc Health. 2012;50:321–3.

  41. 41.

    Springer SC, Silverstein J, Copeland K, et al. Management of type 2 diabetes mellitus in children and adolescents. Pediatrics. 2013;131:e648–64.

  42. 42.

    Kapadia CR. Are the ADA hemoglobin a(1c) criteria relevant for the diagnosis of type 2 diabetes in youth? Curr Diab Rep. 2013;13:51–5.

  43. 43.

    Di Bonito P, Pacifico L, Chiesa C, et al. Impaired fasting glucose and impaired glucose tolerance in children and adolescents with overweight/obesity. J Endocrinol Investig. 2017 Apr;40(4):409–16.

  44. 44.

    Maffeis C, Pinelli L, Brambilla P, et al. Fasting plasma glucose (FPG) and the risk of impaired glucose tolerance in obese children and adolescents. Obesity (Silver Spring). 2010;18:1437–42.

  45. 45.

    Bedogni G, Gastaldelli A, Manco M, et al. Relationship between fatty liver and glucose metabolsim: a cross-sectional study in 571 obese children. Nutr Metab Cardiovasc Dis. 2012;22:120–6.

  46. 46.

    Morandi A, Maschio M, Marigliano M, et al. Screening for impaired glucose tolerance in obese children and adolescents: a validation and implementation study. Pediatr Obes. 2014;9:17–25.

  47. 47.

    Manco M, Grugni G, Di Pietro M, et al. Triglycerides-to-HDL cholesterol ratio as screening tool for impaired glucose tolerance in obese children and adolescents. Acta Diabetol. 2016;53:493–8.

  48. 48.

    Korsten-Reck U, Kromeyer-Hauschild K, Korsten K, Baumstark MW, Dickhuth HH, Berg A. Frequency of secondary dyslipidemia in obese children. Vasc Health Risk Manag. 2008;4:1089–94.

  49. 49.

    Casavalle PL, Lifshitz F, Romano LS, et al. Prevalence of dyslipidemia and metabolic syndrome risk factor in overweight and obese children. Pediatr Endocrinol Rev. 2014;12:213–23.

  50. 50.

    Morrison JA, Glueck CJ, Woo JG, Wang P. Risk factors for cardiovascular disease and type 2 diabetes retained from childhood to adulthood predict adult outcomes: the Princeton LRC follow-up study. Int J Pediatr Endocrinol. 2012;2012:6.

  51. 51.

    National Institutes of Health National Heart, Lung, and Blood Institute. Expert panel on integrated pediatric guideline for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128:S1–S446.

  52. 52.

    Peterson AL, McBride PE. A review of guidelines for dyslipidemia in children and adolescents. WMJ. 2012;111:274–81.

  53. 53.

    Campagna F, Martino F, Bifolco M, et al. Detection of familial hypercholesterolemia in a cohort of children with hypercholesterolemia: results of a family and DNA-based screening. Atherosclerosis. 2008;196:356–64.

  54. 54.

    Pacifico L, Bonci E, Andreoli G, et al. Association of serum triglyceride-to-HDL cholesterol ratio with carotid artery intima-media thickness, insulin resistance and nonalcoholic fatty liver disease in children and adolescents. Nutr Metab Cardiovasc Dis. 2014;24:737–43.

  55. 55.

    Di Bonito P, Valerio G, Grugni G, et al. Comparison of non-HDL-cholesterol versus triglycerides-to-HDL-cholesterol ratio in relation to cardiometabolic risk factors and preclinical organ damage in overweight/obese children: the CARITALY study. Nutr Metab Cardiovasc Dis. 2015;25:489–94.

  56. 56.

    Di Bonito P, Moio N, Scilla C, et al. Usefulness of the high triglyceride-to-HDL cholesterol ratio to identify cardiometabolic risk factors and preclinical signs of organ damage in outpatient children. Diabetes Care. 2012;35:158–62.

  57. 57.

    Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics. 2006;118:1388–93.

  58. 58.

    Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut. 2009;58:1538–44.

  59. 59.

    Schwimmer JB, Dunn W, Norman GJ, et al. SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease. Gastroenterology. 2010;138:1357–64. 1364.e1-2

  60. 60.

    Koot BG, van der Baan-Slootweg OH, Tamminga-Smeulders CL, et al. Lifestyle intervention for non alcoholic fatty liver disease: prospective cohort study of its efficacy and factors related to improvement. Arch Dis Child. 2011;96:669–74.

  61. 61.

    Vajro P, Lenta S, Socha P, et al. Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN hepatology committee. J Pediatr Gastroenterol Nutr. 2012;54:700–13.

  62. 62.

    Nobili V, Alkhouri N, Alisi A, et al. Retinol-binding protein 4: a promising circulating marker of liver damage in pediatric nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7:575–9.

  63. 63.

    Lebensztejn DM, Wierzbicka A, Socha P, et al. Cytokeratin-18 and hyaluronic acid levels predict liver fibrosis in children with non-alcoholic fatty liver disease. Acta Biochim Pol. 2011;58:563–6.

  64. 64.

    Alkhouri N, Mansoor S, Giammaria P, Liccardo D, Lopez R, Nobili V. The development of the pediatric NAFLD fibrosis score (PNFS) to predict the presence of advanced fibrosis in children with nonalcoholic fatty liver disease. PLoS One. 2014;9:e104558.

  65. 65.

    Marzuillo P, Grandone A, Perrone L, Miraglia Del Giudice E. Controversy in the diagnosis of pediatric non-alcoholic fatty liver disease. World J Gastroenterol. 2015;21:6444–50.

  66. 66.

    Goyal NP, Schwimmer JB. The progression and natural history of pediatric nonalcoholic fatty liver disease. Clin Liver Dis. 2016;20:325–38.

  67. 67.

    Maffeis C, Banzato C, Rigotti F, et al. Biochemical parameters and anthropometry predict NAFLD in obese children. J Pediatr Gastroenterol Nutr. 2011;53:590–3.

  68. 68.

    Kaechele V, Wabitsch M, Thiere D, et al. Prevalence of gallbladder stone disease in obese children and adolescents: influence of the degree of obesity, sex, and pubertal development. J Pediatr Gastroenterol Nutr. 2006;42:66–70.

  69. 69.

    Mehta S, Lopez ME, Chumpitazi BP, Mazziotti MV, Brandt ML, Fishman DS. Clinical characteristics and risk factors for symptomatic pediatric gallbladder disease. Pediatrics. 2012;129:e82–8.

  70. 70.

    Heida A, Koot BG, vd Baan-Slootweg OH, et al. Gallstone disease in severely obese children participating in a lifestyle intervention program: incidence and risk factors. Int J Obes. 2014;38:950–3.

  71. 71.

    Svensson J, Makin E. Gallstone disease in children. Semin Pediatr Surg. 2012;21:255–65.

  72. 72.

    Koebnick C, Smith N, Black MH, et al. Pediatric obesity and gallstone disease. J Pediatr Gastroenterol Nutr. 2012;55:328–33.

  73. 73.

    Fradin K, Racine AD, Belamarich PF. Obesity and synmptomatic cholelithiasis in childhood: epidemiologic and case-control evidence for a strong relationship. J Pediatr Gastroenterol Nutr. 2014;58:102–6.

  74. 74.

    Størdal K, Johannesdottir GB, Bentsen BS, Carlsen KC, Sandvik L. Asthma and overweight are associated with symptoms of gastro-oesophageal reflux. Acta Paediatr. 2006;95:1197–201.

  75. 75.

    Malaty HM, Fraley JK, Abudayyeh S, et al. Obesity and gastroesophageal reflux disease and gastroesophageal reflux symptoms in children. Clin Exp Gastroenterol. 2009;2:31–6.

  76. 76.

    Pashankar DS, Corbin Z, Shah SK, Caprio S. Increased prevalence of gastroesophageal reflux symptoms in obese children evaluated in an academic medical center. J Clin Gastroenterol. 2009;43:410–3.

  77. 77.

    Teitelbaum JE, Sinha P, Micale M, Yeung S, Jaeger J. Obesity is related to multiple functional abdominal diseases. J Pediatr. 2009;154:444–6.

  78. 78.

    Koebnick C, Getahun D, Smith N, Porter AH, Der-Sarkissian JK, Jacobsen SJ. Extreme childhood obesity is associated with increased risk for gastroesophageal reflux disease in a large population-based study. Int J Pediatr Obes. 2011;6:e257–63.

  79. 79.

    Davies I, Burman-Roy S, Murphy MS. Guideline development group. Gastro-oesophageal reflux disease in children: NICE guidance. BMJ. 2015;350:g7703.

  80. 80.

    Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41–7.

  81. 81.

    Azziz R, Carmina E, Dewailly D, et al. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. J Clin Endocrinol Metab. 2006;91:4237–45.

  82. 82.

    Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS). Hum Reprod. 2012;27:14–24.

  83. 83.

    Carmina E, Oberfield SE, Lobo RA. The diagnosis of polycystic ovary syndrome in adolescents. Am J Obstet Gynecol. 2010;203:201–5.

  84. 84.

    Conway G, Dewailly D, Diamanti-Kandarakis E, et al. European survey of diagnosis and management of the polycystic ovary syndrome: results of the ESE PCOS special interest Group's questionnaire.; ESE PCOS special interest group. Eur J Endocrinol. 2014;171:489–98.

  85. 85.

    Santamaria F, Montella S, Pietrobelli A. Obesity and pulmonary disease: unanswered questions. Obes Rev. 2012;13:822–33.

  86. 86.

    Delgado J, Barranco P, Quirce S. Obesity and asthma. J Investig Allergol Clin Immunol. 2008;18:420–5.

  87. 87.

    Verhulst SL, Aerts L, Jacobs S, et al. Sleep-disordered breathing, obesity, and airway inflammation in children and adolescents. Chest. 2008;34:1169–75.

  88. 88.

    Kang KT, Weng WC, Lee PL, Hsu WC. Central sleep apnea in obese children with sleep-disordered breathing. Int J Obes. 2014;38:27–31.

  89. 89.

    Boxer GH, Bauer AM, Miller BD. Obesity-hypoventilation in childhood. Am J Acad Child Adolesc Psychiatry. 1988;27:552–8.

  90. 90.

    Rosen CL. Clinical features of obstructive sleep apnea hypoventilation syndrome in otherwise healthy children. Pediatr Pulmonol. 1999;27:403–9.

  91. 91.

    American Academy of Pediatrics. Diagnosis and management of childhood obstructive sleep apnea syndrome. Pediatrics. 2012;130:713–56.

  92. 92.

    Gachelin E, Reynaud R, Dubus JC, Stremler-Le BN. Detection and treatment of respiratory disorders in obese children: obstructive sleep apnea syndrome and obesity hypoventilation syndrome. Arch Pediatr. 2015;22:908–15.

  93. 93.

    McLachlan CR, Poulton R, Car G, et al. Adiposity, asthma, and airway inflammation. J Allergy Clin Immunol. 2007;119:634–9.

  94. 94.

    Santamaria F, Montella S, De Stefano S, et al. Asthma, atopy, and airway inflammation in obese children. J Allergy Clin Immunol. 2007;120:965–7.

  95. 95.

    Vitelli O, Tabarrini A, Miano S, et al. Impact of obesity on cognitive outcome in children with sleep-disordered breathing. Sleep Med. 2015;16:625–30.

  96. 96.

    Wearing SC, Hennig EM, Byrne NM, Steele JR, Hills AP. Musculoskeletal disorders associated with obesity: a biomechanical perspective. Obes Rev. 2006;7:239–50.

  97. 97.

    Chan G, Chen CT. Musculoskeletal effects of obesity. Curr Opin Pediatr. 2009;21:65–70.

  98. 98.

    Bhatia NN, Pirpiris M, Otsuka NY. Body mass index in patients with slipped capital femoral epiphysis. J Pediatr Orthop. 2006;26:197–9.

  99. 99.

    Loder RT, Skopelja EN. The epidemiology and demographics of slipped capital femoral epiphysis. ISRN Orthop. 2011;2011:486512.

  100. 100.

    Sabharwal S. Blount disease: an update. Orthop Clin North Am. 2015;46:37–47.

  101. 101.

    Bout-Tabaku S, Shults J, Zemel BS, et al. Obesity is associated with greater valgus knee alignment in pubertal children, and higher body mass index is associated with greater variability in knee alignment in girls. J Rheumatol. 2015;42:126–33.

  102. 102.

    Jankowicz-Szymanska A, Mikolajczyk E. Genu valgum and flat feet in children with healthy and excessive body weight. Pediatr Phys Ther. 2016;28:200–6.

  103. 103.

    Stolzman S, Irby MB, Callahan AB, Skelton JA. Pes planus and paediatric obesity: a systematic review of the literature. Clin Obes. 2015;5:52–9.

  104. 104.

    Loder RT, Aronsson DD, Weinstein SL, Breur GJ, Ganz R, Leunig M. Slipped capital femoral epiphysis. Instr Course Lect. 2008;57:473–98.

  105. 105.

    Harris EJ, Vanore JV, Thomas JL, et al. Diagnosis and treatment of pediatric flatfoot. J Foot Ankle Surg. 2004;43:341–73.

  106. 106.

    Taylor ED, Theim KR, Mirch MC, et al. Orthopedic complications of overweight in children and adolescents. Pediatrics. 2006;117:2167–74.

  107. 107.

    Lazar-Antman MA, Leet AI. Effects of obesity on pediatric fracture care and management. J Bone Joint Surg Am. 2012;94:855–61.

  108. 108.

    Valerio G, Gallè F, Mancusi C, et al. Prevalence of overweight in children with bone fractures: a case control study. BMC Pediatr. 2012;12:166.

  109. 109.

    Skaggs DL, Loro ML, Pitukcheewanont P, Tolo V, Gilsanz V. Increased body weight and decreased radial cross-sectional dimensions in girls with forearm fractures. J Bone Miner Res. 2001;16:1337–42.

  110. 110.

    Bachrach LK, Sills IN. Section on endocrinology. Bone densitometry in children and adolescents. Pediatrics. 2011;127:189–94.

  111. 111.

    Wang Y, Chen X, Song Y, Caballero B, Cheskin LJ. Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int. 2008;73:19–33.

  112. 112.

    Savino A, Pelliccia P, Chiarelli F, Mohn A. Obesity-related renal injury in childhood. Horm Res Pædiatrics. 2010;73:303–11.

  113. 113.

    Filler G, Reimão SM, Kathiravelu A, Grimmer J, Feber J, Drukker A. Pediatric nephrology patients are overweight: 20 years’ experience in a single Canadian tertiary pediatric nephrology clinic. Int Urol Nephrol. 2007;39:1235–40.

  114. 114.

    Espinoza R, Gracida C, Cancino J, Ibarra A. Effect of obese living donors on the outcome and metabolic features in recipients of kidney transplantation. Transplant Proc. 2006;38:888–9.

  115. 115.

    Burgert TS, Dziura J, Yeckel C, et al. Microalbuminuria in pediatric obesity: prevalence and relation to other cardiovascular risk factors. Int J Obes. 2006;30:273–80.

  116. 116.

    Hirschler V, Molinari C, Maccallini G, Aranda C. Is albuminuria associated with obesity in school children? Pediatr Diabetes. 2010;11:322–30.

  117. 117.

    Savino A, Pelliccia P, Giannini C, et al. Implications for kidney disease in obese children and adolescents. Pediatr Nephrol. 2011;26:749–58.

  118. 118.

    Franchini S, Savino A, Marcovecchio ML, Tumini S, Chiarelli F, Mohn A. The effect of obesity and type 1 diabetes on renal function in children and adolescents. Pediatr Diabetes. 2015;16:427–33.

  119. 119.

    Goknar N, Oktem F, Ozgen IT, et al. Determination of early urinary renal injury markers in obese children. Pediatr Nephrol. 2015;30:139–44.

  120. 120.

    Stevenson SB. Pseudotumor cerebri: yet another reason to fight obesity. J Pediatr Health Care. 2008;22:40–3.

  121. 121.

    Markey KA, Mollan SP, Jensen RH, Sinclair AJ. Understanding idiopathic intracranial hypertension: mechanisms, management, and future directions. Lancet Neurol. 2016;15:78–91.

  122. 122.

    Paley GL, Sheldon CA, Burrows EK, Chilutti MR, Liu GT, McCormack SE. Overweight and obesity in pediatric secondary pseudotumor cerebri syndrome. Am J Ophthalmol. 2015;159:344–52.

  123. 123.

    Brara SM, Koebnick C, Porter AH, Langer-Gould A. Pediatric idiopathic intracranial hypertension and extreme childhood obesity. J Pediatr. 2012;161:602–7.

  124. 124.

    Salpietro V, Chimenz R, Arrigo T, Ruggieri M. Pediatric idiopathic intracranial hypertension and extreme childhood obesity: a role for weight gain. J Pediatr. 2013;162:1084.

  125. 125.

    Stiebel-Kalish H, Serov I, Sella R, Chodick G, Snir M. Childhood overweight or obesity increases the risk of IIH recurrence fivefold. Int J Obes. 2014;38:1475–7.

  126. 126.

    Bassan H, Berkner L, Stolovitch C, Kesler A. Asymptomatic idiopathic intracranial hypertension in children. Acta Neurol Scand. 2008;118:251–5.

  127. 127.

    Friedman DI, Liu GT, Digre KB. Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology. 2013;81:1159–65.

  128. 128.

    Ravid S, Shahar E, Schiff A, Gordon S. Obesity in children with headaches: association with headache type, frequency, and disability. Headache. 2013;53:954–61.

  129. 129.

    Oakley CB, Scher AI, Recober A, Peterlin BL. Headache and obesity in the pediatric population. Curr Pain Headache Rep. 2014;18:416.

  130. 130.

    Robberstad L, Dyb G, Hagen K, Stovner LJ, Holmen TL, Zwart JA. An unfavorable lifestyle and recurrent headaches among adolescents: the HUNT study. Neurology. 2010;75:712–7.

  131. 131.

    Verrotti A, Agostinelli S, D'Egidio C, et al. Impact of a weight loss program on migraine in obese adolescents. Eur J Neurol. 2013;20:394–7.

  132. 132.

    Anderson SE, Cohen P, Naumova EN, Jacques PF, Must A. Adolescent obesity and risk for subsequent major depressive disorder and anxiety disorder: prospective evidence. Psychosom Med. 2007;69:740–7.

  133. 133.

    Roth B, Munsch S, Meyer A, Isler E, Schneider S. The association between mothers psychopatology, childrens’ competences and psychopatological well-being in obese children. Eat Weight Disord. 2008;13:129–36.

  134. 134.

    Vander Wal JS, Mitchell ER. Psychological complications of pediatric obesity. Pediatr Clin N Am. 2011;58:1393–401.

  135. 135.

    Latzer Y, Stein D. A review of the psychological and familial perspectives of childhood obesity. J Eat Disord. 2013;1:7.

  136. 136.

    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington: American Psychiatric Association; 2013.

  137. 137.

    Glasofer DR, Tanofsky-Kraff M, Eddy KT, et al. Binge eating in overweight treatment-seeking adolescents. J Pediatr Psychol. 2007;32:95–105.

  138. 138.

    Sonneville KR, Calzo JP, Horton NJ, et al. Childhood hyperactivity/inattention and eating disturbances predict binge eating in adolescence. Psychol Med. 2015;22:1–10.

  139. 139.

    Amianto F, Ottone L, Abbate Daga G, Fassino S. Binge-eating disorder diagnosis and treatment: a recap in front of DSM-5. BMC Psychiatry. 2015;15:70.

  140. 140.

    Astrup A, Raben A, Geiker N. The role of higher protein diets in weight control and obesity-related comorbidities. Int J Obes. 2015;39:721–6.

  141. 141.

    Epstein LH, Valoski A, Wing RR, McCurley J. Ten-year follow-up of behavioral, family-based treatment for obese children. JAMA. 1990;264:2519–23.

  142. 142.

    Golan M, Weizman A. Familial approach to the treatment of childhood obesity: conceptual model. J Nutr Educ Behav. 2001;33:102–7.

  143. 143.

    Golan M, Crow S. Targeting parents exclusively in the treatment of childhood obesity: long-term results. Obes Res. 2004;12:357–61.

  144. 144.

    Hollands GJ, Shemilt I, Marteau TM, et al. Portion, package or tableware size for changing selection and consumption of food, alcohol and tobacco. Cochrane Database Syst Rev 2015; 9:CD011045.

  145. 145.

    Barlow SE, Expert Committee. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics. 2007;120(Suppl 4):S164–92.

  146. 146.

    Burrows TL, Martin RJ, Collins CE. A systematic review of the validity of dietary assessment methods in children when compared with the method of doubly labeled water. J Am Diet Assoc. 2010;110:1501–10.

  147. 147.

    Burke LE, Wang J, Sevick AM. Self-monitoring in weight loss: a systematic review of the literature. J Am Diet Assoc. 2011;111:92–102.

  148. 148.

    Jääskeläinen A, Schwab U, Kolehmainen M, Pirkola J, Järvelin MR, Laitinen J. Associations of meal frequency and breakfast with obesity and metabolic syndrome traits in adolescents of northern Finland birth cohort 1986. Nutr Metab Cardiovasc Dis. 2013;23:1002–9.

  149. 149.

    Schlundt DG, Hill JO, Sbrocco T, Pope-Cordle J, Sharp T. The role of breakfast in the treatment of obesity: a randomized clinical trial. Am J Clin Nutr. 1992;55:645–51.

  150. 150.

    Spear BA, Barlow SE, Ervin C, et al. Recommendations for treatment of child and adolescent overweight and obesity. Pediatrics. 2007;120(Suppl 4):S254–88.

  151. 151.

    James J, Thomas P, Cavan D, Kerr D. Preventing childhood obesity by reducing consumption of carbonated drinks: cluster randomised controlled trial. BMJ. 2004;328:1237.